BioPharma licensing and M&A trends-Reference-Cited by-同舟云学术

BioPharma licensing and M&A trends

Published:2005-04 Issue:4 Volume:4 Page:273-274
ISSN:1474-1776
Container-title:Nature Reviews Drug Discovery
language:en
Short-container-title:Nat Rev Drug Discov

Author:

Pavlou Alex K.,Belsey Mark J.

Publisher

Springer Science and Business Media LLC

Subject

Drug Discovery,Pharmacology,General Medicine

Link

http://www.nature.com/articles/nrd1679.pdf

Reference3 articles.

1. Research and Manufacturers of America (PhRMA). Pharmaceutical Industry Profile 2004 [online], < http://www.phrma.org/publications/publications//2004-03-31.937.pdf >

2. Friedman, M. A. Testimony on 1998 budget proposal [online], < http://www.hhs.gov/asl/testify/t970501b.html > (1997).

3. US FDA. FDA sees rebound in approval of innovative drugs in 2003; new innovation initiative anticipated to speed approvals in years ahead [online], < http://www.fda.gov/bbs/topics/NEWS/2004/NEW01005.html > (2004)

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. On valuing biopharmaceutical product pipelines: an effectuation model and evidence;Journal of Innovation and Entrepreneurship;2015-12

2. Supply licensing when the manufacturer strategically commits to invest in R&D;Naval Research Logistics (NRL);2014-05-24

3. Supply Licensing When the Manufacturer Strategically Commits to Invest in R&D;SSRN Electronic Journal;2013

4. M13 Bacteriophage-Activated Superparamagnetic Beads for Affinity Separation;Small;2012-05-23

5. Ensuring Quality Science From “R” to “D”: An Optimal Adoption Strategy for In-Licensing of Pharmaceutical Innovation;IEEE Transactions on Engineering Management;2011-11